Alkermes (ALKS) Cash from Financing Activities (2010 - 2026)

Alkermes (ALKS) reported Cash from Financing Activities of $1.5 billion for Q1 2026, up 197292.1% year-over-year from N/an in Q1 2025, and up 13412.82% quarter-over-quarter from $10.9 million in Q4 2025.

Alkermes (ALKS) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has 17 years of Cash from Financing Activities data on file, last reported at $1.5 billion in Q1 2026.

  • Cash from Financing Activities for Q1 2026 came in at $1.5 billion, up 197292.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 412.53% YoY), and the FY2025 annual result was $12.4 million, up 102.51% from the prior year.
  • Cash from Financing Activities rose to $1.5 billion in Q1 2026 per ALKS's latest filing, from $10.9 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $1.5 billion in Q1 2026 and troughed at -$281.7 million in Q4 2024.
  • A 5-year average of $41.3 million and a median of -$212000.0 in 2022 frame the typical range for Cash from Financing Activities.
  • The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities slumped 101928.41% in 2023, then jumped 197292.1% in 2026.
  • A 5-year view of Cash from Financing Activities shows it stood at -$271000.0 in 2022, then tumbled by 101928.41% to -$276.5 million in 2023, then retreated by 1.87% to -$281.7 million in 2024, then soared by 103.87% to $10.9 million in 2025, then jumped by 13412.82% to $1.5 billion in 2026.
  • Business Quant data shows ALKS's Cash from Financing Activities at $1.5 billion in Q1 2026, $10.9 million in Q4 2025, and $315000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 13.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -840.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -1.48 Bn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -86.10 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -65.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 1.47 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -77.88 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn -11.62 Mn
10 Liquidia 5.64 Bn 5.42 Bn 121.79 Mn -18.05 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.47 Bn
Mar 31, 2026 1.47 Bn
Dec 31, 2025 10.91 Mn
Dec 31, 2025 10.91 Mn
Sep 30, 2025 315,000.00
Sep 30, 2025 315,000.00
Jun 30, 2025 405,000.00
Jun 30, 2025 405,000.00
Mar 31, 2025 747,000.00
Mar 31, 2025 747,000.00
Dec 31, 2024 -281.67 Mn
Dec 31, 2024 -281.67 Mn
Sep 30, 2024 -111.11 Mn
Sep 30, 2024 -111.11 Mn
Jun 30, 2024 -83.48 Mn
Jun 30, 2024 -83.48 Mn
Mar 31, 2024 -17.87 Mn
Mar 31, 2024 -17.87 Mn
Dec 31, 2023 -276.50 Mn
Dec 31, 2023 -276.50 Mn